Turing Medical

Executive Summary

Turing Medical is a San Francisco-based medtech company pioneering precision-guided neuromodulation therapies for severe depression and chronic pain. Its proprietary PACE (Personalized Adaptive Cortical Electro-Stimulation) platform integrates advanced functional brain mapping with adaptive cortical stimulation to deliver personalized, image-based targeting. By moving beyond one-size-fits-all approaches, Turing aims to significantly improve outcomes in patients who are refractory to conventional treatments. The platform's closed-loop design adjusts stimulation parameters in real-time based on neural feedback, potentially enhancing both efficacy and tolerability. The market opportunity is substantial: over 300 million people worldwide suffer from depression, and chronic pain affects ~20% of adults. Existing neuromodulation options like TMS and DBS have limited response rates and remain underutilized. Turing's differentiated approach could capture significant share by addressing the heterogeneity of brain circuit dysfunction. With an experienced leadership team and growing interest in precision psychiatry, Turing is well-positioned to advance through clinical development. Near-term milestones, including initial clinical data and regulatory filings, will be key value drivers.

Upcoming Catalysts (preview)

• Q3 2026Phase I/II clinical trial results for depression70% success
• Q4 2026FDA Breakthrough Device Designation80% success
• H1 2027Strategic partnership with a major neurology center60% success